cIAP Pan-specific Antibody [B1J9]

製品コード:F6710

印刷

生物学的記述

Specificity cIAP Pan-specific Antibody [B1J9] detects endogenous levels of total cIAP Pan-specific protein.
Background cIAP1 and cIAP2 are closely related inhibitor of apoptosis family members with N‑terminal tandem baculoviral IAP repeat domains, a central caspase‑recruitment domain, and a C‑terminal RING finger that confers ubiquitin E3 ligase activity, positioning them as scaffold enzymes at TNF receptor–associated signaling complexes and other receptor platforms. The BIR domains bind caspases and other signaling proteins, but sequence analyses and mutagenesis show that cIAP BIRs have substitutions in key residues required for tight caspase inhibition, so their primary biochemical activity arises from RING‑dependent ubiquitination rather than potent direct caspase blockade. The RING domain dimerizes and interacts with ubiquitin‑charged E2 enzymes, catalyzing K63 and other polyubiquitin chains on substrates such as RIP1 at the TNF receptor 1 complex, which creates docking sites for TAK1, IKK, and other NF‑κB pathway components and supports prosurvival and proinflammatory transcriptional responses after TNFα stimulation. Either cIAP1 or cIAP2 is sufficient to maintain RIP1 polyubiquitination and NF‑κB activation upon TNFα treatment, and genetic loss of both proteins leads to reduced RIP1 ubiquitination, diminished NF‑κB signaling, and increased formation of RIP1–FADD–caspase‑8 complexes that execute apoptosis. cIAPs also autoubiquitinate and ubiquitinate other adaptors in TNF and related pathways, contributing to turnover of components and to the balance between survival signaling and cell death complexes in response to cytokine and pattern‑recognition receptor inputs. Mitochondria‑derived Smac/DIABLO and HtrA2/Omi bind the BIR domains through IAP‑binding motifs and promote RING‑dependent autoubiquitination and proteasomal degradation of cIAP1 and cIAP2, which lowers cellular cIAP levels and shifts signaling from NF‑κB activation toward caspase‑8 activation and apoptosis in death receptor pathways. Small‑molecule Smac mimetics bind cIAP BIRs, relieve intramolecular inhibition of the RING domain, induce rapid RING‑mediated autoubiquitination, and trigger proteasomal clearance of cIAP1 and, to a lesser extent, cIAP2, providing a tool to experimentally deplete cIAPs and study the resulting switch from prosurvival to proapoptotic signaling. Elevated cIAP1 and cIAP2 expression is reported in multiple cancers, and their E3 ligase activity toward RIP1 and other targets has been linked to maintenance of constitutive NF‑κB activity and survival of malignant cells under stress, while pharmacologic or genetic disruption of cIAP function sensitizes tumor cells to TNF family ligands and chemotherapeutic agents.

使用情報

Application WB Dilution
WB
1:2000
Reactivity Human, Mouse
Source Mouse Monoclonal Antibody MW 68 kDa
Storage Buffer PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
Storage
(from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

References

  • https://pubmed.ncbi.nlm.nih.gov/18570872/
  • https://pubmed.ncbi.nlm.nih.gov/18697935/

Application Data